Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Start Making Profits Now With T, PFE and QCOM

Marketwired March 18, 2013

Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly

PR Newswire March 18, 2013

A Forward Look, The Year Ahead - Research Report on Pfizer Inc., The Boeing Company, Lockheed Martin Corporation, Barclays PLC and HSBC Holdings plc

PR Newswire March 13, 2013

StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie

PR Newswire March 12, 2013

Secrets to Making Money in MSFT, AIG, PFE and XOM

Marketwired March 11, 2013

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.

Business Wire March 10, 2013

The Reason It Trades, What's Moving PFE, QCOM, JNJ and MRK

Marketwired March 8, 2013

Strategy Behind Our Success, We Get in Early: PFE, GE, IBM and CELG

Marketwired March 7, 2013

Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood

PR Newswire March 7, 2013

Before the Crowd, How We Found INTC, JCP, PFE and GE

Marketwired March 6, 2013

United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex® (celecoxib capsules)

Business Wire March 5, 2013

Key to Success, How to Profit: PFE, MO, LNKD and TXN

Marketwired March 5, 2013

Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13® In Adults With HIV

Business Wire March 4, 2013

Next Week's Trade Setups, What's in Store for PFE, ABT, MDLZ and COF

Marketwired March 1, 2013

The Real Story Behind MS, PFE, HFC and QCOM

Marketwired February 27, 2013

Today's Technical View on PFE, JNJ and MRK

Marketwired February 22, 2013

Opportunity Knocks, Timing Is Everything With T, CELG, PFE and VLO

Marketwired February 21, 2013

Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures

Business Wire February 21, 2013

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire February 19, 2013

Earnings Help Fuel S&P 500 Index Rally -- S&P 500 Index Tops 1500 Mark for the First Time in 5 Years

Marketwired February 19, 2013